AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04199754
Drug: Omnipaque 300mg/mL Solution for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prior to the contrast enhanced Cone Beam CT, 100mL of Omnipaque will be administered by IV at a rate of 2mL per second, followed by administration of 50mL of 0.9% saline.
Trial: NCT04199754
Drug: 0.9% Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 ML of 0.9% Saline will be administered immediately after Omnipaque administration
Trial: NCT02947139
Drug: Co-administration of DWC20155/DWC20156
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02947139
Drug: DWC20161
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00199186
Drug: methotrexate (intrathecal)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00199186
Drug: AraC (intrathecal)
RxNorm normalized name: beractant
DrugBank: Beractant (DB06761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02739711
Drug: Glycoprotein IIb/IIIa inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycoprotein IIb/IIIa inhibitors intravenous bolus followed by an intravenous infusion for 12/18 h plus medical standard therapy
Trial: NCT03662334
Drug: Rapid Acting insulin with pre-treatment of rHuPH20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hylenex recombinant will be administered via infusion sets and insulin pumps. These will be compatible with component tubing system attached to the insulin infusion site and will be placed in the lower abdominal area.
Trial: NCT00309777
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin once daily
Trial: NCT01016483
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00514449
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 pills twice a day x 2 weeks, after 2 weeks 3 pills twice a day x 16 weeks along with antipsychotic
Trial: NCT02355379
Drug: LV5FU2 or capectitabine
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02355379
Drug: FOLFOX4 or XELOX
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02355379
Drug: LV5FU2 or capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01424566
Drug: Placebo (GA-0034)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02226510
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules (with an identical appearance to the active drug) containing only microcrystalline cellulose PhEur will be administered.
Trial: NCT02005601
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive placebo drug with no active ingredients per dose. 1 capsule will be taken pre-operatively. One capsule once a day until end of POD14.
Trial: NCT00724035
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 50 µg iv bolus prn for pain during surgery, up to 150 µg
Trial: NCT04444700
Drug: Therapeutic anticoagulation
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The choice of low molecular weight heparin (LMWH) versus unfractionated heparin (UFH) will be at the clinician's discretion. LMWH options include: Tinzaparin, Enoxaparin or Dalteparin. UFH will be administered using a weight-based nomogram with titration according to center-specific institutional protocol.
Trial: NCT03151525
Drug: Azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: AZA treatment after IFX withdrawal for maintenance of remission
Trial: NCT04311476
Drug: 0.9% Sodiun Chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% Sodiun Chloride in control group
Trial: NCT03388125
Drug: Injection Sclerotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% ethanolamine oleate group
Trial: NCT02137772
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets, or intravenous solution in 250 mL to be infused over 60 minutes.
Trial: NCT00581126
Drug: Recombinant Factor IX Coagulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benefix IV each 12 hours for 2 a 5 days
Trial: NCT01455571
Drug: HM781-36B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Q1DX14/2W for 3W HM781-36B
Trial: NCT00247390
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramelteon placebo-matching tablets, orally, once daily for up to 42 weeks.
Trial: NCT01949662
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo consisting of preservative free 0.9% normal saline given one time by vein.
Trial: NCT01253460
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 250 mg/m2 by vein (IV) over 30 minutes, 2 hours following the dose of Sapacitabine on days 1, 2, and 3 of each 28 day course.
Trial: NCT01819220
Drug: hydrochlorothiazide/telmisartan
RxNorm normalized name: HYDROCHLOROTHIAZIDE/TELMISARTAN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: When the blood pressure is above the target goal of 140/90mmHg, uptitration to amlodipine 5/valsartan 160 and/or telmisartan 80/hydrochlorothiazide 12.5mg is allowed.~When the blood pressure is above 140/90mmhg at the 12th week, addition of doxazosin 4mg is allowed.
Trial: NCT00865462
Drug: Wellbutrin XL® 150 mg Tablet, single dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B: Active comparator Subjects received GlaxoSmithKline formulated products under fed conditions
Trial: NCT00991172
Drug: Placebo Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Subcutaneous injection
Trial: NCT00048906
Drug: DRX005B
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00627640
Drug: Safinimide 50-100 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Safinamide, (S)-(+)-2-\[4-(3-fluorobenzyloxy) benzylamino\] propanamide methanesulfonate, is an a-aminoamide derivative
Trial: NCT00627640
Drug: Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo
Trial: NCT03648996
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 months of placebo treatment
Trial: NCT01930734
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline solution 0.9% Placebo Arm
Trial: NCT01856634
Drug: Optimized Background Regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selection and administration of the treatment medications (i.e. OBRs) will be based on WHO's Guidelines for the programmatic management of drug-resistant TB, in conjunction with national TB program guidelines in each country
Trial: NCT01752517
Drug: NI group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vinorelbine 25mg/m2 d1,d8; ifosfamide 1.25g/m2 d1-d3; Mesna 400mg iv 0,4,8 hours after ifosfamide administration for 3 days
Trial: NCT00317941
Drug: Betaferon/Betaseron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250ug administrated with Betaject
Trial: NCT00317941
Drug: Betaferon/Betaseron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250ug administrated with Betaject light
Trial: NCT01259297
Drug: Placebo for Hydrochlorothiazide (HCTZ)
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo for HCTZ 12.5/25 mg
Trial: NCT02595060
Drug: inhaled placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: formulated as the active substance without molgramostim
Trial: NCT00004865
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00592501
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given as continuous infusion over 4 days starting on the day cisplatin is received after radiation therapy.
Trial: NCT03894904
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 units/mL heparin administered as soon as the arterial catheter is placed and secured, and 2 units/mL heparin administered one hour after initial dose
Trial: NCT02014532
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in Placebo Group were treated with scaling and root planing (SRP) along with Placebo therapy, 1 tablet twice daily for 3 weeks.
Trial: NCT00690937
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01051388
Drug: Non-PPI (Gefarnate)
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The mucosal defensive drug (Gefarnate 50 mg Capsule, twice a day, for four weeks times three)
Trial: NCT03174860
Drug: Diclofenac Potassium 50mg Tab
RxNorm normalized name: DICLOFENAC POTASSIUM 50MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A 50 mg tablet of the medication to be taken one hour before initiation of endodontic treatment.
Trial: NCT03174860
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A placebo will be taken one hour before initiation of endodontic treatment.
Trial: NCT00436215
Drug: BAY 43-9006
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY 43-9006 200 mg po (by mouth) twice daily 5 out of 7 days each week (Mon-Fri)
Trial: NCT01531218
Drug: azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: azithromycin, oral use, 500mg per day for 3 days in total. Total dose 1500mg
Trial: NCT01531218
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04523285
Drug: TQB3728
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQB3728 tablets is a small molecule oral drug.
Trial: NCT00001693
Drug: Celecoxib (SC-58635)
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03536429
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3'100m
Trial: NCT02644525
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of placebo pill is given
Trial: NCT02769572
Drug: placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 grams per knee, 4 times per day, for 4 weeks
Trial: NCT02769572
Drug: diclofenac sodium gel
RxNorm normalized name: diclofenac sodium Topical Gel
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 4 grams per knee, 4 times per day, for 4 weeks
Trial: NCT03230175
Drug: Systemic antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Six (6) weeks of systemic antibiotic therapy is required. A definitive therapy will be guided by the microbiological results based on bone biopsy.
Trial: NCT01459107
Drug: Bone marrow cell-based therapy & single-drug immunosuppression.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This protocol uses a novel bone marrow cell-based therapy for composite tissue allotransplantation (CTA) rather than conventional triple-drug immunosuppression to facilitate long-term graft survival of deceased donor human upper extremities under low-dose maintenance immunosuppression. Initial T-cell depletion with alemtuzumab is followed by upper extremity transplantation and tacrolimus maintenance therapy. Donor bone marrow cells are infused on Day 10 (±4 days) post-transplantation to elicit a host alloimmune response triggering exhaustion and deletion of the respective host (anti-donor) lymphocyte clones. Subsequently, tacrolimus therapy is given for at least 6 months before spaced weaning is considered in stable recipients.
Trial: NCT03344159
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Spironolactone 12.5mg daily up to a maximum dose of 50 mg daily if tolerated for a total duration of 12 weeks.
Trial: NCT03344159
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo daily for a total of duration of 12 weeks
Trial: NCT00772512
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule, single dose
Trial: NCT00962065
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo dosing with daily oral intake for 28 days
Trial: NCT03499041
Drug: LY3314814
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT03042611
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet
Trial: NCT00690716
Drug: Nasal CO2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adaptive Randomization to a Dosing Regimen for Treatment of a Qualifying Headache
Trial: NCT00690716
Drug: Inactive Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adaptive Randomization to a Dosing Regimen for Treatment of a Qualifying Headache
Trial: NCT03428191
Drug: Remifentanyl+Dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In all patients, dexmedetomidine was injected at a bolus of 0.6 mg/kg and then continuously infused at 0.6 ug/kg/h using the conventional continuous microinfusion pump. the target Effect-site concentration of remifentanil was determined by sequential method.
Trial: NCT00348972
Drug: Lantus® (insulin glargine)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01539837
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Feriprox placebo administered orally at the same dosing volume as the 20mg/kg/day feriprox per day
Trial: NCT00960440
Drug: CP-690,550
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets administered at 5 mg BID daily for 6 months during the double-blind, placebo-controlled period.
Trial: NCT00960440
Drug: CP-690,550
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets administered at 10 mg BID daily for 6 months during the double-blind, placebo-controlled period.
Trial: NCT00960440
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo tablets administered BID daily during the first 3 months of the double-blind, study period.
Trial: NCT00960440
Drug: CP-690,550
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets administered at 5 mg BID daily during the second 3 months of the double-blind, study period.
Trial: NCT00960440
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo tablets administered BID daily during the first 3 months of the double-blind, placebo-controlled period.
Trial: NCT00960440
Drug: CP-690,550
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets administered at 10 mg BID daily during the second 3 months of the double-blind, study period.
Trial: NCT01099839
Drug: ASP1941
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT00046319
Drug: BSF 208075
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02889510
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-week subcutaneous placebo once daily
Trial: NCT03799003
Drug: ASP1951
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenously (IV)
Trial: NCT01591746
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mL 0.9% NaCl solution to mimic Botulinum Toxin Type A
Trial: NCT02690480
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo orally once daily from day 1 to day 21 followed by 7 days off treatment on every 28 days cycles.~Patients will continue to receive their assigned treatment until objective disease progression, clinical progression (under investigator criteria), unacceptable toxicity, death or withdrawal of consent, whichever occurs firs
Trial: NCT03177837
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3200m
Trial: NCT04125693
Drug: Combination drug
RxNorm normalized name: combination drugs used in erectile dysfunction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any other drug specified in the protocol of the completed Bayer clinical trials that is used in combination with rogaratinib. Not all patients receive combination therapy.
Trial: NCT02348216
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered according to package insert
Trial: NCT02348216
Drug: High-dose methylprednisolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered according to package insert
Trial: NCT00909987
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PO 1000 mg/m2 bid during day 1 to 15 for 3 cycles (every cycle has 3 weeks)
Trial: NCT00909987
Drug: Capecitabine during all Radiotherapy period
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 825 mg/m2 bid
Trial: NCT02348216
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered according to package insert
Trial: NCT00525317
Drug: Nycoplus Magnesium (120 mg x 3 daily for 2 weeks)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg x 3 or placebo
Trial: NCT00562159
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo sublingual tablet
Trial: NCT04194216
Drug: Intra-operative single intravenous(iv) dose of cephalexin 2 g or clindamycin 900 mg.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment Arm A
Trial: NCT04194216
Drug: Intra-operative single dose (iv) of cephalexin 2 g or clindamycin 900 mg and postoperative oral dose of cephalexin 250mg (every 4 hours) or clindamycin 150mg(every 6 hours) for 3 days
RxNorm normalized name: clindamycin Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment Arm B
Trial: NCT02606045
Drug: recombinant von Willebrand factor
RxNorm normalized name: VON WILLEBRAND FACTOR,RECOMBINANT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group I will receive Arm A recombinant von Willebrand factor 40 IU/kg intravenously (IV) infusion on day 1 of each of two menstrual cycles, Cycles 1 and 2. They will then be crossed over to Arm B, TA 650 mg 2 tablets orally (po) three times daily on days 1-5 of each of two menstrual cycles, Cycles 3 and 4.~Group II will receive Arm B, TA 650 mg 2 tablets orally (po) three times daily on days 1-5, for each of two menstrual cycles, Cycles 1 and 2. They will then be crossed over to Arm A, rVWF 40 IU/kg intravenously (IV) infusion on day 1 on each of two menstrual cycles, Cycles 3 and 4.
Trial: NCT03585374
Drug: Ketoprofen
RxNorm normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Each site will use the commercial available product already in use as per local clinical practice. The drug will be intravenously administered at a 100 mg dose. The time of infusion should be not longer than 10 minutes.
Trial: NCT00637273
Drug: placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablet, once a day
Trial: NCT00637273
Drug: placebo once weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous injection, once a week
Trial: NCT02616029
Drug: E/C/F/TAF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150/150/200/10 mg FDC tablets administered orally once daily
Trial: NCT00461266
Drug: Antiretroviral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As prescribed
Trial: NCT01530399
Drug: MDCO 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDCO-2010 will be administered as a loading dose followed by a continuous infusion until sternal closure. In addition, the CPB reservoir will be primed with MDCO-2010. MDCO 1: load 15 μg/kg; infusion 30 μg/kg/h; CPB prime 0.11 μg/mL priming volume
Trial: NCT01530399
Drug: MDCO 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDCO-2010 will be administered as a loading dose followed by a continuous infusion until sternal closure. In addition, the CPB reservoir will be primed with MDCO-2010. MDCO 2: load 30 μg/kg; infusion 60 μg/kg/h; CPB prime 0.22 μg/mL priming volume
Trial: NCT01530399
Drug: MDCO 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDCO-2010 will be administered as a loading dose followed by a continuous infusion until sternal closure. In addition, the CPB reservoir will be primed with MDCO-2010. MDCO 3: load 60 μg/kg ; infusion 120 μg/kg/h; CPB prime 0.44 μg/mL priming volume
Trial: NCT02166593
Drug: Pravastatin40mg/Fenofibrate160mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravafenix(Pravastatin40mg/Fenofibrate160mg)
Trial: NCT00542685
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules, oral, placebo BID, 8 weeks with 2 week taper.
Trial: NCT03479879
Drug: Estradiol
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estradiol
Trial: NCT03479879
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00000539
Drug: pravastatin
RxNorm normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no